337 related articles for article (PubMed ID: 21704029)
1. Inhibition of angiogenesis involves in anticancer activity of riccardin D, a macrocyclic bisbibenzyl, in human lung carcinoma.
Sun CC; Zhang YS; Xue X; Cheng YN; Liu HP; Zhao CR; Lou HX; Qu XJ
Eur J Pharmacol; 2011 Sep; 667(1-3):136-43. PubMed ID: 21704029
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effect of riccardin D on growth of human non-small cell lung cancer: in vitro and in vivo studies.
Xue X; Sun DF; Sun CC; Liu HP; Yue B; Zhao CR; Lou HX; Qu XJ
Lung Cancer; 2012 Jun; 76(3):300-8. PubMed ID: 22261315
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activities of synthetic and natural stilbenes through antiangiogenic action.
Kimura Y; Sumiyoshi M; Baba K
Cancer Sci; 2008 Oct; 99(10):2083-96. PubMed ID: 19016770
[TBL] [Abstract][Full Text] [Related]
4. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
5. Riccardin D-26, a synthesized macrocyclic bisbibenzyl compound, inhibits human hepatocellular carcinoma growth through induction of apoptosis in p53-dependent way.
Yue B; Zhang YS; Xu HM; Zhao CR; Li YY; Qin YZ; Wang RQ; Sun D; Yuan Y; Lou HX; Qu XJ
Cancer Lett; 2013 Jan; 328(1):104-13. PubMed ID: 22995069
[TBL] [Abstract][Full Text] [Related]
6. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
Li X; Wang X; Ye H; Peng A; Chen L
Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
[TBL] [Abstract][Full Text] [Related]
7. LYP, a bestatin dimethylaminoethyl ester, inhibited cancer angiogenesis both in vitro and in vivo.
Gao JJ; Xue X; Gao ZH; Cui SX; Cheng YN; Xu WF; Tang W; Qu XJ
Microvasc Res; 2011 Sep; 82(2):122-30. PubMed ID: 21664364
[TBL] [Abstract][Full Text] [Related]
8. Riccardin D-26, a synthesized macrocyclic bisbibenzyl compound, inhibits human oral squamous carcinoma cells KB and KB/VCR: In vitro and in vivo studies.
Yue B; Zhao CR; Xu HM; Li YY; Cheng YN; Ke HN; Yuan Y; Wang RQ; Shi YQ; Lou HX; Qu XJ
Biochim Biophys Acta; 2013 Jan; 1830(1):2194-203. PubMed ID: 23085067
[TBL] [Abstract][Full Text] [Related]
9. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
Wang D; Tang F; Wang S; Jiang Z; Zhang L
Cancer Chemother Pharmacol; 2012 Jan; 69(1):173-83. PubMed ID: 21638122
[TBL] [Abstract][Full Text] [Related]
10. Riccardin D, a macrocyclic bisbibenzy, inhibits human breast cancer growth through the suppression of telomerase activity.
Sun CC; Xu HM; Yuan Y; Gao ZH; Lou HX; Qu XJ
Basic Clin Pharmacol Toxicol; 2014 Dec; 115(6):488-98. PubMed ID: 24836118
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of intestinal adenoma formation in APC(Min/+) mice by Riccardin D, a natural product derived from liverwort plant Dumortiera hirsuta.
Liu HP; Gao ZH; Cui SX; Sun DF; Wang Y; Zhao CR; Lou HX; Qu XJ
PLoS One; 2012; 7(3):e33243. PubMed ID: 22432006
[TBL] [Abstract][Full Text] [Related]
12. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.
Kaur G; Belotti D; Burger AM; Fisher-Nielson K; Borsotti P; Riccardi E; Thillainathan J; Hollingshead M; Sausville EA; Giavazzi R
Clin Cancer Res; 2004 Jul; 10(14):4813-21. PubMed ID: 15269157
[TBL] [Abstract][Full Text] [Related]
14. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1.
Chen HH; Zhou HJ; Wu GD; Lou XE
Pharmacology; 2004 May; 71(1):1-9. PubMed ID: 15051917
[TBL] [Abstract][Full Text] [Related]
16. Fisetin inhibits various attributes of angiogenesis in vitro and in vivo--implications for angioprevention.
Bhat TA; Nambiar D; Pal A; Agarwal R; Singh RP
Carcinogenesis; 2012 Feb; 33(2):385-93. PubMed ID: 22139440
[TBL] [Abstract][Full Text] [Related]
17. The antiparasitic drug, potassium antimony tartrate, inhibits tumor angiogenesis and tumor growth in nonsmall-cell lung cancer.
Wang B; Yu W; Guo J; Jiang X; Lu W; Liu M; Pang X
J Pharmacol Exp Ther; 2015 Jan; 352(1):129-38. PubMed ID: 25352499
[TBL] [Abstract][Full Text] [Related]
18. Harmine inhibits tumour specific neo-vessel formation by regulating VEGF, MMP, TIMP and pro-inflammatory mediators both in vivo and in vitro.
Hamsa TP; Kuttan G
Eur J Pharmacol; 2010 Dec; 649(1-3):64-73. PubMed ID: 20858484
[TBL] [Abstract][Full Text] [Related]
19. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
20. Tumor angiogenesis promoted by ex vivo differentiated endothelial progenitor cells is effectively inhibited by an angiogenesis inhibitor, TK1-2.
Oh HK; Ha JM; O E; Lee BH; Lee SK; Shim BS; Hong YK; Joe YA
Cancer Res; 2007 May; 67(10):4851-9. PubMed ID: 17510415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
